2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4496 124I-evuzamitide PET/CT accurately detected AL cardiac amyloidosis and identified extracardiac organ involvement: Results from the phase 3 REVEAL trial

Ravi Kishore Narra, MD.,MS, Ahmad Masri, M.D.2, Mathew S Maurer, M.D3, Omar AbouEzzeddine4, Sarah Cuddy5, spencer guthrie6, Mazen Hanna, Co-Director, Amyloidosis Center Section of Heart Failure and Cardiac Transplant7, michel khouri8, Joshua Mitchell9, Cesia gallegoskattan10, Brett sperry11, Jonathan Wall12, James Udelson13, Angela Dispenzieri, MD14, Sharmila Dorbala, MD, MPH15
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Oregon Health & Science University (OHSU) Knight Cardiovascular Institute, PORTLAND, United States
3 Columbia University Irving Medical Center, New York, United States
4 Mayo Clinic, Rochester, MN, United States
5 Harvard Medical School, Boston, United States
6 Bayer, SFO, United States
7 Cleveland Clinic, Cleveland, United States
8 Duke University Medical Center, Durham, NC, United States
9 Washington University in St. Louis, St. Louis, United States
10 Yale University Medical Center, New Haven, United States
11 University of Missouri-Kansas City, Kansas City, United States
12 University of Tennessee Graduate School of Medicine, Knoxville, United States
13 Tufts University School of Medicine, Boston, United States
14 Mayo clinic, Rochester, MN, United States
15 Brigham and Women's Hospital / Harvard Medical School, Boston, United States

Introduction: Patients with suspected systemic light chain (AL) cardiac amyloidosis require urgent evaluation yet the need for biopsy for diagnostic confirmation frequently introduces diagnostic delays that are known to increase mortality. The REVEAL Phase 3 trial met its primary endpoint showing 124I-evuzamitide PET/CT can accurately identify patients with cardiac amyloidosis. We now report the results on the population with AL amyloidosis in this trial evaluating if a single amyloid-targeting PET scan can noninvasively detect AL amyloidosis, map organ involvement, and distinguish AL from transthyretin (ATTR) amyloidosis.

Methods: The REVEAL study (ClinicalTrials.gov Identifier: NCT06788535) was a prospective, multicenter Phase 3 diagnostic-accuracy study. 170 participants with suspected cardiac amyloidosis from 18 US sites underwent 124I-evuzamitide PET/CT (intent-to-image population). The PET scans were read centrally blinded to clinical data. Diagnosis of cardiac amyloidosis was established by an independent adjudication-committee based on biopsy, bone tracer cardiac scintigraphy, and multimodal imaging, blinded to the 124I-evuzamitide PET/CT data. Diagnostic performance of 124I-evuzamitide PET/CT for AL cardiac amyloidosis was a prespecified secondary endpoint. Extracardiac organ uptake and central laboratory measured light-chain markers were examined in post-hoc analyses. Organ uptake in the spleen, kidney, and liver was measured using standardized uptake value ratio, SUVR, which was defined as the ratio of tracer activity in the organ to blood pool activity. Organ thresholds of abnormal evuzamitide uptake were defined as >mean plus 2 standard deviations above the mean from in-study controls without cardiac amyloidosis.

Results: The cardiac amyloidosis cohort included 75 patients (21 AL, 54 ATTR); 26 in total had AL amyloidosis, including 5 (19%) with systemic AL and no confirmed cardiac involvement. The AL cardiac amyloidosis cohort showed advanced features at time of diagnosis: median NT-proBNP 2,635 ng/L (IQR 1,365 to 5,597), median eGFR 62 mL/min/1.73 m2 (IQR 44 to 74), NYHA class II or III in 21 of 26 (81%), and predominantly Mayo 2004 stage III (23 of 26, 88%); none were stage 1. The sensitivity of 124I-evuzamitide PET/CT for diagnosis of AL cardiac amyloidosis was 95% (95% CI, 76 to 100) with negative predictive value (NPV) 86% (95% CI, 77 to 92). Partial-body PET revealed two or more organs involved (most often heart and spleen) in 19 of 26 AL (73%). At prespecified thresholds, increased kidney (SUVR >3.27) was present in 6 of 26 AL (23%) and liver uptake (>2.93) in 3 of 26 AL (12%); they did not discriminate AL from ATTR and also occurred in controls (7% and 1%). Splenic uptake (SUVR >1.7, above the maximum in ATTR, 1.69, and controls, 1.62) discriminated AL from ATTR amyloidosis: splenic uptake was present in 18 of 26 AL (69%) and in none of the ATTR patients (0 of 54, 0%). Among ATTR patients absence of splenic uptake could further reduce the index of suspicion for AL cardiac amyloidosis: 11 of 54 (20%) ATTR patients had abnormal monoclonal protein, 19 of 54 (35%) an abnormal free light-chain ratio, and 33 of 54 (61%) an elevated involved free light chain, but none had increased splenic uptake.

Conclusions: 124I-evuzamitide PET/CT accurately identified AL cardiac amyloidosis with high sensitivity and NPV It also identified extracardiac AL amyloidosis providing the basis for whole body AL amyloidosis staging. Increased splenic uptake reliably distinguished AL from ATTR, including in patients with monoclonal protein abnormalities. These findings support a role for 124I-evuzamitide PET alongside the hematologic workup to identify suspected AL amyloidosis

Ravi Kishore Narra, MD.,MS: AstraZenica - Honoraria; Sanofi - Honoraria; AstraZenica - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)